A retrospective review combining observational data from three referral centres in Korea has underlined the potential benefits of the immunosuppressant drug mycophenolate mofetil (MMF) in patients with neuromyelitis optica (NMO). In a drug-efficacy analysis involving 58 patients with NMO, MMF treatment was associated with reduced relapse frequency, as well as stabilization or improvement of disability. The authors propose that the drug warrants futher investigation in a larger randomized clinical trial.
References
Huh, S.-Y. et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 10.1001/jamaneurol.2014.2057
Rights and permissions
About this article
Cite this article
Mycophenolate mofetil—a viable treatment option for neuromyelitis optica?. Nat Rev Neurol 10, 547 (2014). https://doi.org/10.1038/nrneurol.2014.173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2014.173